Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Norbert De Clercq"'
Autor:
Nora Dellepiane, Sonia Pagliusi, Prashant Akut, Sebastian Comellas, Norbert De Clercq, Shubhangi Ghadge, Thierry Gastineau, Mic McGoldrick, Ida Nurnaeni, Lorenz Scheppler
Publikováno v:
Vaccine: X, Vol 6, Iss , Pp 100075- (2020)
A comparison of the regulations and guidelines from 33 countries, across different regions, on the requirements and procedures for the management of chemical, manufacturing and control (CMC) changes for vaccines, also known as post- approval changes
Externí odkaz:
https://doaj.org/article/46b229cc8edd444ca6e8e075bdd48a84
Autor:
Mic McGoldrick, Thierry Gastineau, Diane Wilkinson, Cristiana Campa, Norbert De Clercq, Andrea Mallia-Milanes, Olivier Germay, Jyothsna Krishnan, M Van Ooij, Michael P Thien, Peter J. Mlynarczyk, Edward Saltus, Florence Wauters, Philippe Juvin, Didier Clenet, Ana Basso, Nora Dellepiane, Sonia Pagliusi, Monique Collaço de Moraes Stávale, Venkatraman H Sivaramakrishnan, Samir Desai
Publikováno v:
Vaccine. 40(9)
Vaccine discovery and vaccination against preventable diseases are one of most important achievements of the human race. While medical, scientifictechnological advancements have kept in pace and found their way into treatment options for a vast major
Publikováno v:
Vaccine. 39(5)
Vaccines continue to play a central role in our ability to prevent disease, save lives, and improve health. The scientific community, including our own researchers, are driven by a shared purpose to improve vaccine technologies and bring the benefits
Autor:
Thierry Gastineau, Norbert De Clercq, Mic McGoldrick, Shubhangi Ghadge, Ida Nurnaeni, Prashant Akut, Nora Dellepiane, Sonia Pagliusi, Lorenz Scheppler, Sebastian Comellas
Publikováno v:
Vaccine: X
Vaccine: X, Vol 6, Iss, Pp 100075-(2020)
Vaccine: X, Vol 6, Iss, Pp 100075-(2020)
Highlights • Assessment of regulations and guidelines from 33 countries reveals complexity. • Variability of regulatory guidance for review and approval of manufacturing changes. • Reliance on the regulatory approval in the country of origin of
Autor:
Geert Leroux-Roels, Isabelle Desombere, Michel Stoffel, Pierre Van Damme, Marie Van der Wielen, Norbert De Clercq, Christian Goilav
Publikováno v:
Vaccine
About 510% of the general adult population respond inadequately to hepatitis B vaccination. The histocompatibility leucocyte antigen (HLA) DQ2, DR3 and DR7 phenotypes have been linked with non-responsiveness to hepatitis B vaccination. A first part o
Autor:
Anamaria Cavalcanti, Sue Ann Costa Clemens, Frank Von Sonnenburg, Françoise Collard, Norbert De Clercq, Robert Steffen, Ralf Clemens
Publikováno v:
Revista Panamericana de Salud Pública, Vol 11, Iss 4, Pp 245-252 (2002)
Objective. To assess the epidemiology and impact of traveler's diarrhea (TD) among visitors to the city of Fortaleza, Ceará, Brazil, as part of a global study on TD carried out in four countries. Methods. Within a cross-sectional survey, questionnai
Autor:
Norbert De-Clercq, Yaela Baine, Dennis L Parenti, Etienne Tordeur, Betsy Abraham, Pascal P Gerard, Patrick L Manouvriez
Publikováno v:
Antiviral Research. 53:63-73
Interference between antibodies generated by a combination hepatitis A and B vaccine was investigated by evaluating the quantity and quality of anti-hepatitis A virus (HAV) and anti-hepatitis B surface antigen (HBs) antibodies generated by Twinrix®
Autor:
Ralf Clemens, Frank von Sonnenburg, Robert Steffen, Françoise Collard, Norbert De Clercq, Sue Ann Costa Clemens, Anamaria Cavalcanti
Publikováno v:
Revista Panamericana de Salud Pública, Vol 11, Iss 4, Pp 245-252 (2002)
Objective. To assess the epidemiology and impact of traveler's diarrhea (TD) among visitors to the city of Fortaleza, Ceara, Brazil, as part of a global study on TD carried out in four countries. Methods. Within a cross-sectional survey, questionnair
Publikováno v:
Vaccine. 19:2400-2403
Studies with recombinant hepatitis B vaccines show seroprotection rates varying between 91 and 100%. Thus, a limited risk may remain for non-responding populations (e.g. non-responders, haemodialysis patients, elderly) who could benefit from a more i
Autor:
Charles Buscarino, Norbert De Clercq, Jeri Beran, Christian Van Hoecke, Betsy Abraham, Denis L. Parenti, Henry M. Feder
Publikováno v:
The Journal of Pediatrics. 135:575-579
Background and Objective: A recombinant lipoprotein vaccine against Lyme disease, containing 30 μg of Borrelia burgdorferi outer surface protein A (OspA) with aluminum adjuvant, has been shown in a large US field trial of subjects ≥15 years of age